24th Sep 2015 14:18
Vectura Group plc
Results of a General Meeting held on 24 September 2015 at the offices of Covington & Burling LLP, 265 Strand, London WC2R 1BH.
Chippenham, UK, 24 September 2015: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), announces that all resolutions proposed to shareholders at the General Meeting held today were duly passed on a poll, the results of which are set out below:
| Resolution | Votes for | % of votes cast | Votes against | % of votes cast | Votes withheld* |
Ordinary Resolutions | ||||||
1 | To approve the Directors' remuneration policy. | 313,344,761
| 96.74
| 10,569,776
| 3.26
| 15,513
|
2 | That the rules of the Vectura Group 2015 Long-Term Incentive Plan ("the Plan") be approved and the Directors be authorised to make modifications to the Plan as they consider appropriate and establish further plans in overseas territories based on the Plan. | 307,865,652
| 95.04
| 16,053,141
| 4.96
| 11,257
|
*NB: The percentage of votes cast for and against excludes withheld votes.
The Company confirms that copies of all resolutions proposed at the General Meeting held earlier today, 24 September 2015, will be submitted to the National Storage Mechanism (NSM) at [email protected] and will shortly be available for viewing.
James Ward-Lilley - appointment as CEO and Executive Director
The Company also announces that, following the announcement made on 24 June 2015, the appointment of James Ward-Lilley as CEO and Executive Director has been confirmed with effect from the close of the General Meeting held today, 24 September 2015, rather than 1 October 2015, as was previously announced.
There are no further disclosures required pursuant to paragraph LR 9.6.13 R of the Listing Rules of the UK Listing Authority in relation to this appointment.
- Ends -
Enquiries:
Vectura Group plc
Andrew J Oakley
Chief Financial Officer and Company Secretary
One Prospect West
Chippenham
Wiltshire
SN14 6FH
Tel: +44 (0)1249 667700
www.vectura.com
Notes for Editors:
About Vectura
Vectura is a product development company that focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). This growing market includes asthma and chronic obstructive pulmonary disease (COPD) and is estimated to be worth $44 billion worldwide.
Vectura now has eight products marketed by partners with growing global royalty streams and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura currently has disclosed development collaborations and licence agreements with several global pharmaceutical and biotechnology companies, including Novartis, Sandoz, Baxter, GlaxoSmithKline, UCB, Ablynx, Grifols, Janssen Biotech and Tianjin KingYork Group Company.
Vectura develops products for airways diseases and owns formulation and inhalation technologies that are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.
For further information, please visit Vectura's website at www.vectura.com.
1 Decision Resources 2014 |
Related Shares:
VEC.L